Cancer glossary
Osimertinib (Tagrisso): tablets for EGFR-mutant lung cancer
Osimertinib is a targeted drug for lung cancer with an EGFR mutation. Who it suits, how to take it, how long treatment lasts and which side effects can occur.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026
In short
Osimertinib (brand name Tagrisso) is a targeted tablet for non-small cell lung cancer with an EGFR mutation. It is a third-generation tyrosine kinase inhibitor: it also works against the T790M mutation that makes earlier-generation drugs stop working.
How it appears in your prescription
- ‘Osimertinib 80 mg orally once a day, continuously’.
- ‘Adjuvant osimertinib’ — after surgery, usually for up to 3 years.
- ‘Osimertinib + chemotherapy’ — a first-line option in advanced disease.
What it means
Osimertinib is only prescribed if a sensitising EGFR mutation is found in the tumor, by PCR or NGS. According to the US National Cancer Institute, it is approved as first-line treatment for metastatic cancer, after progression on other EGFR inhibitors when T790M is present, and after surgery in early stages. In advanced disease, treatment continues as long as it works.
Side effects
Diarrhea, rash and dry skin, inflammation around the nails (paronychia) and mouth sores. Less often: ECG changes (QT prolongation), reduced heart function and lung inflammation. That is why an ECG is done before and during treatment.
Tell your doctor about a new cough or breathlessness, palpitations, fainting or frequent diarrhea.
Questions to ask your doctor
- Which EGFR mutation do I have, and which test found it?
- How often will I have CT scans and ECGs?
- What if the disease starts to progress on the tablets — will I need a repeat biopsy or a liquid biopsy?
More on testing in the article on mutations in lung cancer.
Sources
- Osimertinib Mesylate — National Cancer Institute
- Targeted Drug Therapy for Non-small Cell Lung Cancer — American Cancer Society
- Drugs Approved for Lung Cancer — National Cancer Institute
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
